What is a normal vitamin D level in Australia?

Australian guidelines — endorsed by Healthy Bones Australia and the Endocrine Society of Australia — define sufficient vitamin D as a serum 25-hydroxyvitamin D (25-OH-D) level of 50 nmol/L or above, measured at the end of winter when levels are at their annual lowest. Mild deficiency is 30–49 nmol/L; moderate deficiency 12.5–29 nmol/L; severe deficiency below 12.5 nmol/L. Some specialist groups argue a higher target of 75 nmol/L is better for fall and fracture prevention in older adults, but the current Australian consensus threshold for sufficiency remains 50 nmol/L.

Should everyone be tested for vitamin D deficiency?

No. Choosing Wisely Australia recommends against routine vitamin D testing of asymptomatic people without risk factors. The MBS item 66608 (25-OH vitamin D assay) has specific Medicare-rebatable indications: symptoms or signs of deficiency, malabsorption, deeply pigmented skin or chronic lack of sun exposure, medications affecting vitamin D metabolism, chronic kidney disease, hypocalcaemia, hyperparathyroidism, and monitoring of established vitamin D treatment. Blanket testing in healthy adults without risk factors generates cost without improving outcomes, since supplementation in already-replete adults provides no measurable clinical benefit for cardiovascular disease, cancer, or mortality.

How much sun exposure do I need for adequate vitamin D?

This depends on skin type, season, latitude, and time of day. In Australian summer, people with lighter skin (Fitzpatrick I–III) typically need only a few minutes of incidental midday sun on the face, forearms, and hands most days — the UV index is high enough that brief exposure is sufficient. In winter, longer exposure is needed, particularly in southern cities (Melbourne, Hobart). For people with darker skin (Fitzpatrick IV–VI), the required exposure is three to six times longer; supplementation is often more practical than trying to achieve adequate synthesis. Deliberate sun exposure for vitamin D is not recommended when the UV index is 3 or above; use incidental exposure and supplementation instead.

What is the correct vitamin D supplement to take?

Cholecalciferol (vitamin D3) is preferred over ergocalciferol (vitamin D2) because it produces a more sustained rise in 25-OH vitamin D levels. Most formulations available in Australian pharmacies are cholecalciferol, available over the counter. Doses of 1000–2000 IU daily are appropriate for mild deficiency or maintenance; 3000–5000 IU daily for moderate deficiency with a recheck at three months; 5000 IU daily or 50,000 IU monthly for three months for severe deficiency. Avoid sustained doses above 10,000 IU daily without specialist oversight — vitamin D toxicity, while rare, causes hypercalcaemia and can damage the kidneys. Annual mega-dose injections (500,000 IU) are contraindicated — a randomised trial showed they increase falls and fractures.

Does vitamin D prevent cancer or heart disease?

Based on the evidence currently available, supplementing vitamin D in people who already have sufficient levels does not reduce cancer incidence, cardiovascular events, or all-cause mortality. The large VITAL randomised controlled trial, published in the New England Journal of Medicine in 2019, enrolled more than 25,000 US adults and found no significant reduction in major cardiovascular events or invasive cancer incidence from vitamin D supplementation in people not selected for deficiency. These results are consistent across several other large RCTs. The appropriate use of vitamin D supplementation is to treat or prevent deficiency in at-risk individuals — not as a general health supplement in replete adults.

Vitamin D deficiency

Vitamin D deficiency: testing, supplementation, and sun safety

By Dr HB Lo, FACRRM Reviewed 2 June 2026 9 min read

Vitamin D deficiency affects approximately 30% of Australians at the end of winter, with higher rates in aged care, dark-skinned individuals, and those with malabsorption conditions. Most deficiency is subclinical; significant disease presents as osteomalacia, proximal myopathy, and increased fracture risk.

Management follows a severity-based approach: sensible sun exposure first; cholecalciferol supplementation at 1000–5000 IU daily depending on severity; retest at three months. Routine population screening is not recommended — test those with clinical indications or risk factors. In chronic kidney disease, cholecalciferol is inactive; calcitriol or alfacalcidol is required instead.

Vitamin D deficiency is encountered regularly in Australian general practice — not because Australians lack sunlight overall, but because modern indoor work patterns, sun-protective clothing, high rates of obesity, and the specific needs of people with dark skin or limited sun exposure create significant pockets of deficiency in the population. Healthy Bones Australia estimates approximately 30% of Australians have serum 25-hydroxyvitamin D below 50 nmol/L at the end of winter, with rates approaching 50% in residential aged care and substantially higher among women who cover for religious or cultural reasons.

The clinical significance of vitamin D deficiency lies primarily in its role in calcium homeostasis and bone and muscle function — it is not a general-purpose wellness vitamin. Most deficiency is subclinical. When severe or in at-risk populations, it contributes to osteomalacia, proximal myopathy, falls, and fractures. Choosing Wisely Australia recommends against routine vitamin D testing of asymptomatic adults — the test has specific clinical indications, and supplementing replete adults confers no measurable benefit.

A. Core clinical — the AU general-practice framework

Physiology

Vitamin D is primarily a hormone, not a dietary nutrient in the conventional sense — 80–90% of the body’s requirement is met by cutaneous synthesis from 7-dehydrocholesterol under the action of UVB radiation. Only a small proportion comes from diet (oily fish, egg yolks, fortified margarine, and milk). In Australia, wheat flour used in bread-making is not mandatorily fortified with vitamin D (unlike folic acid).

After skin synthesis or dietary absorption, vitamin D is transported to the liver where it is hydroxylated to 25-hydroxyvitamin D (25-OH-D) — the measurable storage form. The kidney then produces 1,25-dihydroxyvitamin D (calcitriol) — the biologically active form — under parathyroid hormone (PTH) stimulation. In chronic kidney disease (CKD), impaired renal 1α-hydroxylase activity means calcitriol production is reduced despite potentially adequate 25-OH-D. This is why standard cholecalciferol does not correct functional vitamin D deficiency in moderate-to-severe CKD — active forms (calcitriol or alfacalcidol) are required instead.

Classification (AU consensus thresholds)

Per Healthy Bones Australia and the RACGP 2024 Osteoporosis Guideline:

Level	Serum 25-OH-D
Sufficient	≥50 nmol/L
Mild deficiency	30–49 nmol/L
Moderate deficiency	12.5–29 nmol/L
Severe deficiency	<12.5 nmol/L

Note: some specialist groups (including parts of the Endocrine Society of Australia) suggest targeting ≥75 nmol/L in older adults for fall and fracture prevention, but 50 nmol/L remains the Australian general practice consensus threshold.

Risk factors

The following groups are at elevated risk and represent the clinical indications for testing:

Dark skin (Fitzpatrick V–VI) or cultural/religious full-body covering
Housebound, institutionalised, or residential aged care residents
BMI ≥30 (vitamin D is sequestered in adipose tissue, reducing bioavailability)
Malabsorption conditions: coeliac disease, inflammatory bowel disease, bariatric surgery, cystic fibrosis, chronic pancreatitis
Chronic liver disease (impaired 25-hydroxylation) or CKD
Medications increasing vitamin D catabolism: phenytoin, carbamazepine, rifampicin, HIV antiretrovirals, glucocorticoids (CYP-induction)
Breastfed infants of vitamin D-deficient mothers
Clinical features suggesting deficiency

History

Sun exposure pattern (indoor work, shift work, seasonal variation, latitude — Brisbane vs Hobart winter differ substantially); skin type and cultural cover; diet (oily fish, fortified products, supplements); GI symptoms suggesting malabsorption; relevant medications; bone symptoms — pain, fractures, falls; pregnancy and lactation status.

Examination

Most deficiency is asymptomatic. Severe deficiency produces proximal muscle weakness — difficulty rising from a chair without using hands (Trendelenburg gait), difficulty climbing stairs, proximal upper-limb weakness. In advanced osteomalacia: diffuse bone pain and tenderness, and insufficiency fractures. In hypocalcaemia complicating severe deficiency: Chvostek and Trousseau signs. Children: bow legs, rachitic rosary (rib beading), frontal bossing, wrist flaring.

Investigations

First-line (eTG; MBS 66608 restrictions current 2026):

25-OH vitamin D 66608: Medicare-rebatable for specific indications only; private cost otherwise approximately $40
Calcium 66512; phosphate; ALP; PTH 66645; UEC 66500

Second-line / targeted:

Coeliac serology (anti-tTG IgA + total IgA) for unexplained deficiency with GI symptoms
B12, ferritin, FBC 65070 if malabsorption suspected
24-hour urinary calcium if hypercalciuria suspected (especially in granulomatous disease)
DXA 12306: osteoporosis or osteomalacia workup in appropriate clinical context
1,25-dihydroxyvitamin D: only in CKD, granulomatous disease, hypoparathyroidism, or vitamin D-resistant rickets — not for routine deficiency assessment

Important: biotin supplementation interferes with the immunoassay for 25-OH-D; advise ceasing biotin at least 48 hours before testing.

B. Evidence appraisal — what supplementation can and cannot achieve

Vitamin D does not reduce CV events or cancer in replete adults

The VITAL RCT (Manson et al, NEJM 2019) — 25,871 participants, 5-year follow-up — showed no significant reduction in major cardiovascular events, invasive cancer incidence, or all-cause mortality from cholecalciferol supplementation (2000 IU daily) in adults not selected for deficiency. This finding is consistent with multiple other large RCTs. Vitamin D supplementation is appropriate for treating or preventing deficiency; it does not function as a general cardiovascular or cancer-prevention supplement in replete adults.

Annual mega-dose is contraindicated

The Sanders JAMA 2010 RCT (Sanders et al) showed that a single annual oral dose of 500,000 IU cholecalciferol in older women — despite correcting serum levels — increased falls by 15% and fractures by 26% compared to placebo. The mechanism appears to involve supraphysiological spikes overwhelming vitamin D receptor signalling. This trial directly informs the Healthy Bones Australia recommendation against annual mega-dose regimens.

Sun exposure and skin cancer trade-off

The 2024 Healthy Bones Australia / Cancer Council joint position statement represents the current balanced Australian guidance: deliberate sun exposure to prevent or treat vitamin D deficiency is not recommended when the UV index is 3 or above. Incidental, brief sun exposure during outdoor activity is appropriate and adequate for most light-skinned Australians during summer. For darker-skinned Australians, veiled women, and others unable to achieve adequate sun exposure, supplementation is the practical solution. Australia’s skin cancer burden — the highest per-capita in the world — means vitamin D sufficiency cannot justify deliberate UV exposure without risk assessment.

Choosing Wisely on vitamin D testing

Choosing Wisely Australia (RACGP recommendation) advises against routine population vitamin D testing. Population-wide screening of asymptomatic adults generates high test volumes but does not translate to improved health outcomes, since supplementing replete adults is ineffective. The MBS restriction on item 66608 reflects this evidence — document the clinical indication in the request.

C. Management — sun, diet, and supplementation

Sun exposure first

Light skin (Fitzpatrick I–III): a few minutes of incidental midday sun on the face, forearms, and hands most days during summer; longer exposure needed in winter, particularly at high latitudes (Melbourne, Hobart). Use the SunSmart UV index (Cancer Council app) to gauge when UV is adequate for synthesis.

Darker skin (Fitzpatrick IV–VI): three to six times longer UV exposure is required for the same vitamin D synthesis. Supplementation is often more practical than prolonged deliberate sun exposure.

Sun protection when UV ≥3: standard Australian public health advice — apply sunscreen SPF 50+, wear protective clothing, seek shade. This does not mean avoiding all sun; incidental exposure during routine outdoor activity in lower UV conditions contributes to vitamin D.

Dietary sources (modest contribution in Australia)

Oily fish (salmon, mackerel, sardines, tuna), egg yolks, UV-exposed mushrooms, and fortified margarines and milks. Dietary vitamin D alone cannot reliably maintain sufficiency in at-risk groups.

Supplementation by severity

Per eTG, AMH, and Healthy Bones Australia:

Severity	Dose	Duration
Mild (30–49 nmol/L)	Cholecalciferol 1000–2000 IU/day	Long-term if at ongoing risk; or 3 months then reassess
Moderate (12.5–29)	Cholecalciferol 3000–5000 IU/day	6–12 weeks, then 1000–2000 IU/day maintenance; recheck at 3 months
Severe (<12.5)	Cholecalciferol 5000 IU/day or 50,000 IU monthly × 3	→ 1000–2000 IU/day maintenance; recheck at 3 months
CKD (severe/ESRD)	Calcitriol 0.25 mcg/day (titrate with specialist)	Ongoing; monitor calcium

Cholecalciferol (D3) is preferred over ergocalciferol (D2) for more sustained level elevation. Most pharmacy brands in Australia are D3.

Pregnancy and lactation

Standard prenatal multivitamins contain approximately 400 IU vitamin D — adequate for most women. If deficiency is confirmed (25-OH-D <50 nmol/L), additional cholecalciferol 1000–2000 IU daily is safe in pregnancy. Breastfed infants of vitamin D-deficient mothers — or where the mother is dark-skinned, veiled, or housebound — should receive 400 IU cholecalciferol daily from birth; formula-fed infants receive adequate vitamin D from fortified formula.

D. Australian operations

MBS item 66608 (25-OH vitamin D) is Medicare-rebatable for specific clinical indications, not routine screening. The indications include: signs or symptoms of deficiency; malabsorption; deeply pigmented skin or chronic lack of sun exposure; medications affecting vitamin D metabolism; CKD; hypocalcaemia or hypercalcaemia; hyperparathyroidism; exclusion of deficiency in osteomalacia or rickets workup; monitoring of established treatment.

MBS billing for consultations: 23/36/44. 75+ health assessment 705 and ATSI health assessment 715 include vitamin D where clinically relevant. 45–49 health assessment 701 suitable for risk-factor identification.

GPMP/TCA (721/723): vitamin D deficiency alone does not qualify as a GPCCMP-eligible condition; consider where it forms part of a broader chronic disease plan — osteoporosis, CKD, malabsorption syndrome, or fall prevention in aged care.

PBS pbs.gov.au: most cholecalciferol formulations are OTC; calcitriol (Rocaltrol) and alfacalcidol (One-Alpha) are PBS Authority Required for CKD and hypoparathyroidism (specialist initiation).

Document the clinical indication for 66608 testing in the clinical record — Choosing Wisely alignment and audit-proofing.

E. Special populations

Chronic kidney disease

Do not use standard cholecalciferol in moderate-to-severe CKD (eGFR <30–45) — the kidney cannot activate it to calcitriol. Use calcitriol 0.25 mcg daily or alfacalcidol, titrated with calcium monitoring, under specialist or experienced GP supervision. Refer to the renal/endocrinology team for vitamin D management in CKD stages 3b–5.

Granulomatous disease (sarcoidosis, tuberculosis)

Do not give standard vitamin D supplementation without specialist advice. Granulomas contain activated macrophages with autonomous 1α-hydroxylase activity that convert 25-OH-D to calcitriol regardless of PTH signalling. Supplementation can precipitate hypercalcaemia and hypercalciuria, leading to nephrocalcinosis and renal injury. If 25-OH-D is low in a patient with known sarcoidosis, refer to endocrinology before supplementing.

Residential aged care

Institutional vitamin D programmes significantly reduce falls and fractures in this population. Residents should receive 1000–2000 IU cholecalciferol daily as standard care unless specifically contraindicated. Healthy Bones Australia supports this as a universal aged-care prevention measure.

Aboriginal and Torres Strait Islander patients

Despite Australia’s latitude, deficiency is common among Aboriginal and Torres Strait Islander people living in southern Australia, remote areas with limited food variety, or those with comorbid malabsorption conditions. Include vitamin D in annual health assessment pathology where clinically indicated. Culturally safe nutritional support through Aboriginal Health Workers and Aboriginal Medical Services supports adherence.

When to escalate

Refer or escalate when:

Severe symptomatic hypocalcaemia (tetany, seizures, carpopedal spasm) — emergency management of hypocalcaemia
Suspected rickets or osteomalacia in children — paediatric endocrinology
Complex CKD vitamin D management — renal/endocrinology
Known or suspected granulomatous disease (sarcoidosis, TB) requiring supplementation — endocrinology
Vitamin D-resistant rickets or inherited vitamin D metabolism disorders — specialist
Persistent unexplained deficiency despite adequate supplementation and sun exposure — investigate malabsorption (coeliac, IBD, bariatric)

What this article is and is not

This is general health information drawn from current Australian general practice guidelines — Healthy Bones Australia, eTG: Endocrinology, AMH, Endocrine Society of Australia, and RACGP. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about testing, specific doses, and management of comorbid conditions affecting vitamin D are made with your own GP and treating clinicians.

Consumer resources: HealthDirect — Vitamin D deficiency, Better Health Channel — Vitamin D, Healthy Bones Australia — Vitamin D, Cancer Council Australia — UV and skin cancer.

Sources cited

Frequently asked questions

What is a normal vitamin D level in Australia?

Australian guidelines — endorsed by Healthy Bones Australia and the Endocrine Society of Australia — define sufficient vitamin D as a serum 25-hydroxyvitamin D (25-OH-D) level of 50 nmol/L or above, measured at the end of winter when levels are at their annual lowest. Mild deficiency is 30–49 nmol/L; moderate deficiency 12.5–29 nmol/L; severe deficiency below 12.5 nmol/L. Some specialist groups argue a higher target of 75 nmol/L is better for fall and fracture prevention in older adults, but the current Australian consensus threshold for sufficiency remains 50 nmol/L.
Should everyone be tested for vitamin D deficiency?

No. Choosing Wisely Australia recommends against routine vitamin D testing of asymptomatic people without risk factors. The MBS item 66608 (25-OH vitamin D assay) has specific Medicare-rebatable indications: symptoms or signs of deficiency, malabsorption, deeply pigmented skin or chronic lack of sun exposure, medications affecting vitamin D metabolism, chronic kidney disease, hypocalcaemia, hyperparathyroidism, and monitoring of established vitamin D treatment. Blanket testing in healthy adults without risk factors generates cost without improving outcomes, since supplementation in already-replete adults provides no measurable clinical benefit for cardiovascular disease, cancer, or mortality.
How much sun exposure do I need for adequate vitamin D?

This depends on skin type, season, latitude, and time of day. In Australian summer, people with lighter skin (Fitzpatrick I–III) typically need only a few minutes of incidental midday sun on the face, forearms, and hands most days — the UV index is high enough that brief exposure is sufficient. In winter, longer exposure is needed, particularly in southern cities (Melbourne, Hobart). For people with darker skin (Fitzpatrick IV–VI), the required exposure is three to six times longer; supplementation is often more practical than trying to achieve adequate synthesis. Deliberate sun exposure for vitamin D is not recommended when the UV index is 3 or above; use incidental exposure and supplementation instead.
What is the correct vitamin D supplement to take?

Cholecalciferol (vitamin D3) is preferred over ergocalciferol (vitamin D2) because it produces a more sustained rise in 25-OH vitamin D levels. Most formulations available in Australian pharmacies are cholecalciferol, available over the counter. Doses of 1000–2000 IU daily are appropriate for mild deficiency or maintenance; 3000–5000 IU daily for moderate deficiency with a recheck at three months; 5000 IU daily or 50,000 IU monthly for three months for severe deficiency. Avoid sustained doses above 10,000 IU daily without specialist oversight — vitamin D toxicity, while rare, causes hypercalcaemia and can damage the kidneys. Annual mega-dose injections (500,000 IU) are contraindicated — a randomised trial showed they increase falls and fractures.
Does vitamin D prevent cancer or heart disease?

Based on the evidence currently available, supplementing vitamin D in people who already have sufficient levels does not reduce cancer incidence, cardiovascular events, or all-cause mortality. The large VITAL randomised controlled trial, published in the New England Journal of Medicine in 2019, enrolled more than 25,000 US adults and found no significant reduction in major cardiovascular events or invasive cancer incidence from vitamin D supplementation in people not selected for deficiency. These results are consistent across several other large RCTs. The appropriate use of vitamin D supplementation is to treat or prevent deficiency in at-risk individuals — not as a general health supplement in replete adults.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.